India's Parliament Standing Committee has recommended capping the markup of the heart-attack drug Tenecteplase at 20% [3].
The move aims to protect patients from excessive costs during medical emergencies. Because Tenecteplase is a critical clot-dissolving medication used to treat myocardial infarctions, high retail prices can create significant financial barriers to life-saving care.
During a recent meeting, the committee flagged a steep disparity in the pricing structure of the medication [1]. The group said that the landing price of Tenecteplase is approximately ₹18,000 [1]. However, the maximum retail price for the same drug reaches ₹50,000 [2].
This price gap indicates a markup that far exceeds the committee's proposed limit. By recommending a 20% cap on the price gap [3], the committee seeks to align the retail cost more closely with the actual cost of importing or producing the drug.
The committee's findings highlight ongoing tensions between pharmaceutical profit margins and public health accessibility in India. The proposal suggests that the current market-driven pricing for emergency cardiac care is unsustainable for a large portion of the population.
If implemented, the cap would force a drastic reduction in the maximum retail price of the drug. Such a regulation would mark a significant intervention by the government into the pricing of specialized cardiovascular medications.
“India's Parliament Standing Committee has recommended capping the markup of the heart-attack drug Tenecteplase at 20%.”
This proposal reflects a broader effort by the Indian government to curb the high cost of essential medicines. By targeting the gap between landing price and retail price, the committee is addressing 'price gouging' in the pharmaceutical supply chain. If the 20% cap is adopted, it could set a precedent for other life-saving drugs, potentially lowering costs for patients but reducing profit incentives for distributors and pharmacies.
